HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update




HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc.  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update.

Third Quarter and Recent Highlights

During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.

MyoVista Insights™ Healthcare IT Software Platform

• Regulatory classification. MyoVista Insights is classified as a Medical Device Data System (“MDDS”), which carries significantly lower regulatory requirements than medical devices and is exempt from FDA 510(k) clearance. As a result, organizational costs and time to commercial rollout are expected to be substantially lower and faster than those associated with regulated medical devices.

• Platform advancement. Since its early-adopter launch in 2025, the Company has implemented phased upgrades to MyoVista Insights. On March 13, 2026, HeartSciences released a significant version upgrade ahead of the American College of Cardiology (“ACC”) Annual Scientific Session, where the Company will exhibit and publicly introduce the platform to the broader cardiology and healthcare IT community. The upgrade includes mobile phone viewing, reporting enhancements, and significant interoperability improvements designed to support deployment across large health systems.

• Commercial traction. During 2026 the Company’s objectives include establishing key reference sites and generating initial revenues. HeartSciences has already made commercial progress with reference installations and endorsement from a hospital network. Early feedback has been compelling, and the Company is currently in discussions with multiple health systems regarding deployment. Management expects to announce several key customer wins during 2026.

• AI-ECG marketplace opportunity. In addition to generating per-test SaaS revenues as a secure cloud-based ECG data management system, MyoVista Insights is purpose-built to enable the integration of AI-ECG algorithms directly into routine clinical practice through an AI-ECG marketplace. The platform is designed to host third-party algorithms alongside HeartSciences’ own technologies. The Company is currently in discussions with several potential partners to host AI algorithms and believes this model positions HeartSciences to participate in a multi-billion-dollar AI-ECG market opportunity while reducing the cost and time required for algorithm development and regulatory clearance.

• Investor demonstration. Following the public introduction of MyoVista Insights at the ACC Annual Scientific Session, the Company plans to host an investor call to demonstrate the platform and provide additional detail regarding its commercialization strategy and market opportunity.

MyoVista® wavECG™ Device

• The Company submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance in December 2025.

• HeartSciences elected to separate the FDA submissions for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG algorithm following updated guidance published by the American Society of Echocardiography (“ASE”) regarding the assessment of Left Ventricular Diastolic Dysfunction (“LVDD”), including revised age-based thresholds for cardiac relaxation (e’).

Management Commentary

Andrew Simpson, Chief Executive Officer of HeartSciences, said, “We are making strong progress toward our 2026 objectives, including establishing reference sites, commencing revenue generation for MyoVista Insights, making AI algorithms available on the platform, and achieving best-in-class interoperability across hospital systems.”

Mr. Simpson added, “The submission of the MyoVista wavECG device to the FDA represents an important regulatory milestone and advances our broader strategy to modernize ECG through the integration of artificial intelligence.”

Fiscal Third Quarter 2026 Financial Results

HeartSciences reported no meaningful revenue for FQ3 2026 as the Company continues to focus on commercialization of the MyoVista Insights platform.

As of January 31, 2026, the Company had approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity.

Complete financial results are included in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026, which has been filed with the U.S. Securities and Exchange Commission and is available on the Company’s website at www.heartsciences.com.

About HeartSciences

HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.

For more information, please visit: https://www.heartsciences.com. X: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. All statements, other than statements of historical facts, included herein are “forward-looking statements” including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025 filed with the SEC on December 15, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences’ other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us 

Media Contact:
HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com

Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock




Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock

CRANFORD, N.J., March 16, 2026 (GLOBE NEWSWIRE) — Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon’s common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, the offer expires at 5:00 p.m., Eastern Time, on March 19, 2026, unless the offer is further extended.

Continental Stock Transfer & Trust Company, the depositary for the offer, has advised Enzon that, as of 5:00 p.m., Eastern Time, on March 13, 2026, a total of 342 shares of Series C Preferred Stock had been validly tendered and not properly withdrawn, representing less than 1% of the outstanding shares of Series C Preferred Stock (based on 40,000 shares of Series C Preferred Stock outstanding as of March 13, 2026). Holders of Series C Preferred Stock who have previously validly tendered and not withdrawn their shares do not need to re-tender their shares or take any other action in response to this extension.

Except as described in this press release, the terms of the offer remain the same as set forth in the Prospectus/Consent Solicitation/Offer to Exchange filed with the U.S. Securities and Exchange Commission on January 28, 2026 and declared effective on January 30, 2026 (the “Prospectus/Consent Solicitation/Offer to Exchange”), the letter of transmittal, and the notice of guaranteed delivery.

What’s Being Offered

Enzon is offering all holders of outstanding shares of Series C Preferred Stock the chance to exchange their shares for shares of Common Stock. Each share of Series C Preferred Stock can be exchanged for an amount of Common Stock equal to (i) the aggregate liquidation preference of each share of Series C Preferred Stock, divided by (ii) $7.83 after giving effect to the Reverse Stock Split (as defined in the Prospectus/Consent Solicitation/Offer to Exchange).

Key Dates and Information

• Deadline to Participate: The offer expires at 5:00 p.m., Eastern Time, on March 19, 2026, unless further extended.
• Holders of Series C Preferred Stock who elect to participate in the offer can withdraw their tendered shares any time before the deadline.

Offer Details

The offer is described in full in the Prospectus/Consent Solicitation/Offer to Exchange and the Schedule TO (as defined below), filed with the U.S. Securities and Exchange Commission on January 30, 2026.

• Common Stock Symbol: ENZN (quoted on the “OTCQB” tier of the OTC market)
• Preferred Stock: Not publicly traded; 40,000 shares outstanding as of March 13, 2026

HKL & Co., LLC has been appointed as the Information Agent for the offer, and Continental Stock Transfer & Trust Company has been appointed as the Exchange Agent. Requests for documents should be directed to HKL & Co., LLC at +1 (800) 326-5997 (for individuals) or +1 (212) 468-5380 (for banks and brokers) or via the following email address: enzn@hklco.com.

About Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc., together with its subsidiary, is positioned as a public company acquisition vehicle that has sought to become an acquisition platform.

For Media Inquiries:

Richard L. Feinstein, CEO and CFO
Email: rlfeinsteincpa@enzon.com

Important Additional Information Has Been Filed with the SEC

The offer commenced on January 30, 2026. On January 28, 2026, a registration statement on Form S-4 and preliminary prospectus included therein was filed with the SEC by the Company, which was declared effective on January 30, 2026, and on January 30, 2026 an exchange offer statement on Schedule TO (the “Schedule TO”), including an offer to exchange, a letter of transmittal and consent and related documents, was filed with the SEC by the Company. The offer to exchange the outstanding shares of Series C Preferred Stock of the Company will only be made pursuant to the Prospectus/Consent Solicitation/Offer to Exchange and Schedule TO, including related documents filed as a part of the offer. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS/CONSENT SOLICITATION/OFFER TO EXCHANGE AND SCHEDULE TO FILED OR TO BE FILED WITH THE SEC CAREFULLY, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE EXCHANGE OFFER, INCLUDING THE TERMS AND CONDITIONS OF THE EXCHANGE OFFER. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to HKL & Co., LLC at +1 (800) 326-5997 (for individuals) or +1 (212) 468-5380 (for banks and brokers) or via the following email address: enzn@hklco.com. Investors and security holders may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the “Investors” section of the Company’s website at https://investor.enzon.com/.

No Offer or Solicitation

This press release shall not constitute an offer to exchange or the solicitation of an offer to exchange or the solicitation of an offer to purchase any securities, nor shall there be any exchange or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offer is being made only through the Schedule TO and Prospectus/Consent Solicitation/Offer to Exchange, and the complete terms and conditions of the offer are set forth in the Schedule TO and Prospectus/Consent Solicitation/Offer to Exchange.

None of the Company, any of its management or its board of directors, or the Information Agent or the Exchange Agent makes any recommendation as to whether or not holders of shares of Series C Preferred Stock should tender shares of Series Preferred Stock for exchange in the offer.

Forward-Looking Statements

Certain statements contained in this filing may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the proposed transaction involving Enzon and Viskase Companies, Inc. (“Viskase”), the ability to consummate the proposed transaction, the ability to consummate the offer, the timing of the Expiration Date, and the ability to quote the common stock of the combined company on the “OTCQB” tier of the OTC market of the OTC Markets Group, Inc. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the risk that the conditions to the closing of the proposed transaction are not satisfied, including the failure to obtain the necessary approvals for the proposed transaction; (ii) uncertainties as to the timing of the consummation of the proposed transaction, including timing for satisfaction of the closing conditions, and the ability of each of Enzon and Viskase to consummate the proposed transaction; (iii) the ability of Viskase to timely deliver the financial statements required by the Merger Agreement, as amended; (iv) the possibility that other anticipated benefits of the proposed transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the combined company’s operations, and the anticipated tax treatment of the combination; (v) potential litigation relating to the proposed transaction that could be instituted against Enzon, Viskase or their respective officers or directors; (vi) possible disruptions from the proposed transaction that could harm Enzon’s or Viskase’s respective businesses; (vii) the ability of Viskase to retain, attract and hire key personnel; (viii) potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the announcement or completion of the proposed transaction; (ix) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Enzon’s or Viskase’s financial performance; (x) certain restrictions during the pendency of the proposed transaction that may impact Enzon’s or Viskase’s ability to pursue certain business opportunities or strategic transactions; (xi) the exchange ratio and relative ownership levels as of the closing of the transactions contemplated by the Merger Agreement, as amended; (xii) estimates regarding future revenue, expenses, and capital requirements following the closing of the transactions contemplated by the Merger Agreement, as amended; (xiii) legislative, regulatory and economic developments; (xiv) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, trade wars, or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors; and (xv) such other risks and uncertainties, including those that are set forth in the Registration Statement under the heading “Risk Factors”, in Enzon’s periodic public filings with the SEC, and in Viskase’s annual and quarterly reports posted to Viskase’s website. Enzon and Viskase can give no assurance that the conditions to the proposed transaction will be satisfied. Except as required by applicable law, neither Enzon, nor Viskase undertakes any obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value




Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) — Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced the successful settlement of its outstanding litigation involving a former Director. This landmark agreement represents a pivotal financial milestone for the Company, delivering immediate and substantial value to current shareholders by improving the capital structure and strengthening the balance sheet.

Under the terms of the settlement, which is expected to close within 30 days, Exousia Pro will make a one-time, strategic payment of $147,500 to the involved parties. In exchange, the Company will secure highly favorable financial restructuring outcomes.

For the purposes of the Company’s upcoming financial reporting and audits, these events will be recorded under Generally Accepted Accounting Principles (GAAP) and will provide the following distinct benefits to the Company and its shareholders:

• Significant Debt Reduction: The settlement triggers the complete cancellation of a $200,000 promissory note issued at closing, as well as the cancellation of the remaining balance on the note tied to the control block of Preferred Stock. Removing these liabilities immediately strengthens Exousia’s balance sheet and frees up future cash flow.
• Reversal of Share Dilution: The agreement secures the cancellation and return to treasury of 6,297,511 shares of Common Stock. Retiring this sizable block of shares reverses prior dilution, directly increasing the equity value, earnings-per-share potential, and ownership percentage of all current shareholders.
• Enhanced Audit Readiness and Transparency: By formally clearing these contested liabilities and equity issuances from the general ledger under GAAP, the Company is positioned for a clean, streamlined audit. This provides greater financial transparency and reinforces confidence within the investment community.

By resolving this legacy dispute efficiently, Exousia Pro’s management team can now focus entirely on advancing its core clinical pipeline and expanding its telehealth initiatives without the distraction or financial overhang of litigation.

About Exousia Pro, Inc. Exousia Pro, Inc. is a biotechnology company at the forefront of exosome research, focused on developing next-generation delivery systems for therapeutic and diagnostic applications. Through its expanding telehealth division, the Company aims to bridge the gap between clinical innovation and patient access.

Forward-Looking Statements This press release contains forward-looking statements regarding the timing of definitive agreements, the closing of the aforementioned settlement, and the expected benefits of financial restructuring and acquisitions. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those anticipated.

SAFE HARBOR

Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.’s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties’ future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
ir@exousiapro.com

Completion of Share Buy-back Program




Completion of Share Buy-back Program

Company Announcement

COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026.

On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of 725 million DKK to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than March 31, 2026.

The following transactions were executed under the program from March 9, 2026 to March 13, 2026:

Following these transactions, Genmab holds 2,859,663 shares as treasury shares, corresponding to 4.45% of the total share capital and voting rights.

The share buy-back program has been undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 05 dated February 17, 2026.

About Genmab 
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:        
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®.

Company Announcement no. 16
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 160326_CA16_Completion of SBBP

Qolab Announces John Martinis Prize as Momentum Builds for Scalable Quantum Hardware




Qolab Announces John Martinis Prize as Momentum Builds for Scalable Quantum Hardware

Debuting at APS Global Physics Summit with Quantum Machines and IQCC, Alongside New Collaborations, Education Programs, and Hiring Expansion

DENVER, March 16, 2026 (GLOBE NEWSWIRE) — Qolab today announced the launch of the John Martinis Prize for Experimental Superconducting Qubit Physics, a new initiative designed to support the next generation of researchers advancing superconducting quantum hardware. The prize is supported by Qolab, Israeli Quantum Computing Center (IQCC), and Quantum Machines, whose control technology powers the initiative’s experimental framework. The announcement comes as the company highlights a series of technical collaborations, education initiatives, and workforce investments during the American Physics Society (APS) Global Physics Summit in Denver.

Named in honor of Qolab co-founder and CTO John M. Martinis, recipient of the 2025 Nobel Prize in Physics for his pioneering work on macroscopic quantum mechanical tunnelling and energy quantisation in an electric circuit, the prize will provide research and education grants to scientists and educators working to advance experimental superconducting quantum systems.

The program will support both academic research and classroom instruction, providing awardees with funding and access to Qolab quantum processors, running on the Quantum Machines orchestration stack, to accelerate experimental work and training in superconducting qubit control and device engineering.

“Scaling quantum computers from research prototypes to useful systems requires a new generation of experimentalists who understand both the physics and the engineering of superconducting devices,” said John M. Martinis, CTO and co-founder, Qolab. “Through the John Martinis Prize, we hope to support researchers and educators pushing the boundaries of qubit control, device design, and experimental techniques.”

“The IQCC is the only cloud access center providing experimentalists with full pulse-level control of superconducting qubits via Quantum Machines’ OPX+,” said Nir Alfasi, General Manager, IQCC. “We are excited to host Qolab’s processors to advance technology with the next generation of superconducting experimentalists.”

Grant recipients will receive financial support, processor access, and opportunities to collaborate with leading researchers in the field. Research awardees will be granted time on Qolab’s latest superconducting processors hosted at the IQCC, enabling advanced pulse-level control experiments and advanced device characterization, a research stipend, and a free pass to the Adaptive Quantum Circuits conference.

Applications for the John Martinis Prize will open on March 16, and researchers and educators can apply via the online submission form. Prize winners will be formally announced and recognized at the Adaptive Quantum Circuits (AQC) conference in Chicago in 2026.

Global collaborations advancing scalable quantum hardware

The announcement comes amid growing international momentum around Qolab’s approach to scalable superconducting quantum hardware.

Earlier this year, Qolab announced a collaboration with researchers at Singapore’s National Quantum Federated Foundry (NQFF) to develop cryogenic low-pass filters, critical components used to suppress microwave noise in superconducting quantum processors. These components represent a key bottleneck in building larger and more reliable quantum systems.

The collaboration combines Singapore’s advanced semiconductor manufacturing capabilities with Qolab’s expertise in superconducting qubit systems. By developing wafer-scale cryogenic filters that can be integrated directly with quantum processor circuits, the partnership aims to enable denser integration and improved reliability in next-generation quantum computers.

Expanding access to quantum hardware education

At APS, Qolab is also highlighting its Quantum Educational Fabrication Program (Qolab Fab), an initiative designed to bring hands-on quantum hardware engineering into university classrooms.

The program enables students to design superconducting microwave resonators using professional electronic design tools, after which Qolab fabricates and measures the devices at millikelvin temperatures using its production measurement infrastructure.

Students then analyze real measurement data from the devices they designed, providing practical exposure to superconducting circuit engineering and the materials challenges that limit qubit performance.

The program will launch pilot deployments in summer 2026 and is designed to expand access to quantum hardware education, particularly for undergraduate institutions and master’s programs without access to specialized fabrication and cryogenic infrastructure.

Building the quantum workforce

Qolab is also expanding its team and will be participating in the APS Global Physics Summit Career Fair, where prospective candidates can meet members of the Qolab engineering team and speak directly with Nobel laureate John Martinis about careers in quantum hardware.

“As the field moves from laboratory demonstrations to manufacturable systems, there is enormous demand for engineers and physicists who can bridge quantum science and semiconductor manufacturing,” said Alan Ho, CEO, Qolab. “We’re building a team focused on solving the hard engineering problems that determine whether quantum computing can scale.”

Interested applicants can learn more about opportunities at the APS Career Fair or by visiting the Qolab booth #717.

In addition, those interested in hearing Qolab CTO and cofounder, and Nobel Laureate John Martinis, speak can join the following sessions at APS in Denver:

• Quantum in Singapore Booth 820 on March 17 at 11:00
• Quantum Machines Booth 1607 on March 17 at 14:00

About Qolab

Qolab is a hardware company developing utility-scale superconducting quantum computers. By combining deep physics and engineering expertise with strategic semiconductor partnerships, we solve the toughest challenges on the path to fault-tolerant quantum computing.

Media Contact:
Gregory Ho
media@qolab.ai

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference




Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026.

Mr. Levy will be available for 1×1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule.

About Alpha Tau Medical Ltd. 

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT^®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact:
IR@alphatau.com

Nordletics Makes Home Fitness Simple and Personalized




Nordletics Makes Home Fitness Simple and Personalized

Nordletics Helps Users Build Consistent Home Fitness Routines Through Personalized Workouts, Nutrition Guidance, and Habit Tracking

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — Nordletics introduces a home fitness platform designed to help individuals build healthier routines through personalized workouts, practical nutrition guidance, and lifestyle tracking tools. The app combines structured exercise programs, balanced meal planning, and habit support within a single platform created for flexibility and accessibility.

By focusing on simple, equipment-free training and guided daily routines, Nordletics helps users stay consistent with their fitness goals while training comfortably from home.

Personalized Fitness That Adapts to Your Routine

Nordletics begins with a short onboarding quiz analyzing information about a user’s fitness level, goals, schedule, and lifestyle. Based on these responses, the platform creates a personalized program aligned with everyday routines rather than offering a one-size-fits-all plan.

Each Profile Includes:

• Personalized workout plans that adapt to different schedules and fitness levels.
• Custom meal guidance based on dietary needs and personal goals.
• Habit trackers that monitor hydration, movement, and sleep.
• A digital content library with video sessions, articles, and challenges designed to maintain engagement.

Guided Workouts Designed for Home Training

Nordletics emphasizes convenience through equipment-free workouts that can be performed almost anywhere. Sessions typically last between 20 and 45 minutes, making them accessible for people with busy schedules.

The workouts focus on functional bodyweight exercises that build strength, endurance, and mobility. Visual demonstrations and structured session guidance help users follow routines while maintaining proper form.

Because the program adjusts to different ability levels, beginners and experienced users can progress at a comfortable pace.

Transparent Billing and Responsive Customer Support

Nordletics emphasises clarity and accessibility throughout the user experience. Subscription options are presented clearly during checkout, including pricing details, plan duration, and renewal information, so users can review their selection before confirming their subscription.

Customer support is available to assist users with account access, subscription questions, or technical guidance. The support team quickly provides clear responses to help users resolve issues and continue using the platform without unnecessary interruptions.

Conclusion

Nordletics combines personalized workouts, balanced nutrition guidance, and practical habit tracking tools to help individuals build consistent fitness routines from home.

Start your journey today and discover a simple, structured path toward stronger health and sustainable daily habits with Nordletics.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/978281b1-da5a-43cb-a3c8-40c2a5b9d05b

CONTACT: Contact
evita.anilionyte@flmng.ai

PROLLENIUM® Launches VAMP™ Advanced, a Patent-Pending PDRN Solution




PROLLENIUM® Launches VAMP™ Advanced, a Patent-Pending PDRN Solution

A high concentration medical-grade polydeoxyribonucleotide (PDRN) formulation designed for advanced skin rejuvenation

RICHMOND HILL, Ontario, March 16, 2026 (GLOBE NEWSWIRE) — PROLLENIUM®, today launched VAMP™ Advanced, a breakthrough skin rejuvenation treatment that helps improve skin tonicity, tighten pores and smooth wrinkles to restore skin’s glow, hydration and texture. VAMP™ Advanced is a patent-pending, proprietary topical sterile bio-revitalizing solution — an enhanced upgrade of VAMP™, formulated with a potent blend of 5x more medical-grade high purity PDRN, along with vitamins, amino acids, minerals and hyaluronic acid.

Key Ingredients of VAMP™ Advanced:

• 11 Vitamins to support skin rejuvenation, hydration, and aesthetic appearance.
• 23 Amino Acids for improved skin hydration and elasticity, barrier support, even skin tone, and reduced redness due to dryness.
• 6 Minerals to support skin barrier and overall skin health.
• 0.5% concentration PDRN, known to reduce the appearance of aging and tighten and improve skin elasticity¹.
• Hyaluronic Acid to support hydration.

PDRN are fragments of low molecular weight DNA extracted from wild salmon and purified to over 95% to ensure safety, stability, and biocompatibility². Compared to other salmon DNA extracts such as Polynucleotide (PN) and hydrolyzed DNA, PDRN demonstrates clinically proven skin rejuvenation benefits beyond structural support or surface hydration^3-5.

“When evaluating PDRN-based products, I focus on quality and manufacturing standards—including purity and formulation consistency. Evidence suggests that PDRN’s rejuvenating effects are distinct from other DNA derivatives. VAMP™ Advanced contains five times more PDRN than the original formulation, and it’s manufactured in Canada using medical-grade ingredients sterilized for clinical use. For health care professionals focusing on supporting skin quality and radiance, the science behind PDRN and the formulation standards behind VAMP Advanced make it a differentiated option in this category.” said Dr. Katie Beleznay, MD, FRCPC, Dermatologist, Vancouver, BC.

As 78% of consumers are concerned about skin texture and discoloration⁶, and 86% of aesthetics patients are leaning toward treatments that stimulate natural bodily processes⁷, PROLLENIUM^® is committed to empowering aesthetic providers with high-efficacy solutions rooted in skin science. VAMP™ Advanced is intended for topical use, and clinical studies indicate its key ingredient, PDRN, can be used to enhance skin quality and reduce visible signs of aging¹.

The high-concentration PDRN product, VAMP™ Advanced, joins PROLLENIUM^®’s portfolio of physician-directed innovations, including the globally recognized REVANESSE^® HA dermal fillers. It marks the next step in PROLLENIUM^®’s strategic focus on high-efficacy solutions rooted in molecular science. Manufactured to the highest global safety standards, VAMP™ Advanced empowers practitioners to deliver consistently high-impact results.

For more information, please visit the VAMP™ Advanced website here.

Frequently Asked Questions

What is VAMP™ Advanced?

• VAMP™ Advanced is a patent pending, high-concentration, medical-grade polydeoxyribonucleotide (PDRN) solution developed by PROLLENIUM^®. It is designed for professional use in aesthetics to improve skin hydration, texture, and elasticity.

What does VAMP™ Advanced do?

• VAMP™ Advanced is used by professional clinicians to help aesthetics patients tighten pores, smooth wrinkles, improve skin texture, and boost overall hydration. The formula supports skin rejuvenation by combining PDRN with vitamins, amino acids, minerals, and hyaluronic acid.

Is VAMP™ Advanced safe?

• Yes. VAMP™ Advanced uses the highest quality, medical-grade ingredients and is proudly manufactured by PROLLENIUM^® in North American GMP-certified facility that complies with FDA and Health Canada standards.
• As with any aesthetic treatment, possible side effects may occur. These are generally mild and transient, and may include redness or mild local inflammation, mild edema, or small hematomas at the treatment site. Such reactions typically resolve within 24–48 hours without the need for intervention.

What is PDRN?

• PDRN (polydeoxyribonucleotides) are fragments of low molecular weight DNA extracted from wild salmon which are purified to over 95% to ensure safety, stability and biocompatibility². It is known for its ability to inhibit the signs of aging, tighten and improve skin’s elasticity¹.

What are the key ingredients in VAMP™ Advanced?

• VAMP™ Advanced is formulated with:
  • 0.5% medical-grade PDRN – helps tighten skin and improve elasticity
  • 11 Vitamins – deliver hydration and nourishment for healthier-looking skin
  • 23 Amino Acids – reduce visible signs of aging and improve skin tonicity
  • 6 Minerals – support the skin barrier for overall skin health
  • Hyaluronic Acid – provides hydration

Who can use VAMP™ Advanced?

• VAMP™ Advanced is intended for use by medical professionals in clinical settings. It is not available as a consumer over-the-counter product. Patients seeking treatment should consult a licensed provider who offers PROLLENIUM^® aesthetic solutions.

What makes VAMP™ Advanced different from other skin rejuvenation treatments?

• Unlike standard serums or hydrating treatments, VAMP™ Advanced delivers a high concentration of medical grade PDRN combined with bioactive nutrients. This evidence-based formulation is designed for professional use and manufactured to the highest global safety standards in GMP-certified facilities.

Can VAMP™ Advanced be injected?

• No. VAMP™ Advanced is a topical cosmetic product designed for application on the outer layer of the skin (stratum corneum). It should not be injected into the body.

About PROLLENIUM®
Founded in 2002, PROLLENIUM^® is a science-first innovator in facial aesthetics and skin technologies. PROLLENIUM^® is one of the select few manufacturers to have received FDA and Health Canada approval for its state-of-the-art facilities and combines advanced R&D, high-quality manufacturing, and deep expertise in medical aesthetics. Aesthetic professionals trust PROLLENIUM^® brands in over 60 countries.

About VAMP™ Advanced
VAMP™ Advanced developed by PROLLENIUM^®, is a breakthrough skin revitalization treatment powered by polydeoxyribonucleotides (PDRN) and a unique blend of essential nutrients, including amino acids, vitamins, minerals, and non cross-linked low molecular weight hyaluronic acid. Designed for professional use, VAMP™ Advanced is carefully formulated to improve skin hydration and elasticity while reducing visible signs of aging. Proudly manufactured in North America in facilities meeting GMP standards, VAMP™ Advanced represents PROLLENIUM^®’s continued commitment to science-driven, next-generation aesthetic solutions.

Media Inquiries:
Talk Shop Media
Prollenium@talkshopmedia.com

References:

1. Khan A et al., CJPRS. 2022;4:187.
2. Squadrito F et al., Frontiers in Pharmacology. 2017;8:224.
3. Liu E. Four kinds of PDRN ingredients explained for private label brands. Metro Private Label – Skin Care Manufacturer. 2025. Available from: https://www.metroprivatelabel.com/kinds-pdrn-ingredients-explained-private-label-brands/. Accessed November 12, 2025.
4. Unlocking the benefits of sodium DNA for skin health [Internet]. 2024. Available from: https://www.lwlmedspa.com/unlocking-the-benefits-of-sodium-dna-for-skin-health. Accessed November 12, 2025.
5. Wishtrend. Vegan vs salmon PDRN: which is best for skin regeneration? 2025. Available from: https://wishtrend.com/en-ca/blogs/glam/vegan-vs-salmon-pdrn-guide. Accessed November 12, 2025.
6. American Society for Dermatologic Surgery. 2025 ASDS Consumer Survey on Cosmetic Dermatologic Procedures. 2025.
7. NewBeauty. 2025. NewBeauty Supplement: Summer 2025. https://issuu.com/newbeauty/docs/newbeauty_supplement_summer_2025

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/06c35d20-6921-448e-b3d3-e85a79010131

Solve GNE Highlights New Research, Expands Funding Efforts, and Advances Toward a Phase I Clinical Trial for GNE Myopathy




Solve GNE Highlights New Research, Expands Funding Efforts, and Advances Toward a Phase I Clinical Trial for GNE Myopathy

LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) — Solve GNE, a nonprofit foundation dedicated to accelerating treatments for GNE myopathy, has announced major progress across its research, fundraising, and regulatory efforts. To date, the non-profit has raised more than $6.5 million in support of programs aimed at moving clinically viable therapies closer to approval.

A newly published preclinical paper highlights the recent progress in one of our clinical development programs for GNE myopathy¹. The study, which was carried out in collaboration with Gradalis Inc., describes a series of in vitro and in vivo data associated with a dual-function plasmid called GNEwt/bi-shRNA-GNEM743T lipoplex, designed to simultaneously deliver the wild-type GNE gene (GNEwt) and shut off the expression of GNEM743T, a GNE mutation that is highly prevalent in the Iranian Jewish community. Gradalis researchers showed that this approach leads to clinically relevant expression levels of functioning GNE protein as well as increased sialic acid production. The lack of sialic acid production is a hallmark of GNE Myopathy and is suspected to be the leading cause of muscle loss in these patients. Animal models showed that the engineered plasmid was successfully delivered to muscle tissue after intravenous administration using a DOTAP-cholesterol lipoplex formulation. Together, these findings support continued development of this gene therapy and help lay the foundation for future clinical testing in GNE myopathy.

Solve GNE and its collaborators are also pursuing several grant opportunities to support the next phases of research and development in GNE Myopathy. These grant applications are focused on the development of safer AAV based gene therapies, as well as novel blood-based biomarkers, gene editing approaches, the validation of a diagnostic platform to help predict immune responses to AAV-based therapies and further supporting the development of a clinically scalable dbRNA lipoplex treatment. If successful, these grant applications represent approximately $10.2 million in potential federal funding with the possibility of additional funding in the future.

Funding from Solve GNE is also being directed at the filing of an IND application by Gradalis Inc. in 2026. The FDA reviewed and provided a series of comments to our pre-IND application. Our team is currently finalizing the IND application for the first gene therapy targeting GNE Myopathy and we anticipate that a Phase I clinical trial may begin within the next 12-months.

Solve GNE remains focused on turning scientific progress into real momentum for GNE Myopathy patients and their families. Our commitment to funding additional research will help build a stronger path toward future treatment options for this rare disease.

About Solve GNE
Solve GNE is a nonprofit foundation dedicated to advancing research and treatment development for GNE myopathy. Through fundraising and scientific partnerships, Solve GNE works to accelerate progress toward therapies for patients and families affected by this rare muscle disease.

Media Contact:
Alexander Monsef
AlexM@solveGNE.org

____________________________

¹ Preclinical assessment of GNEwt/bi-shRNA-GNEM743T lipoplex product development for GNE myopathy. Future Science OA, 12:1, 2635722, DOI: 10.1080/20565623.2026.2635722

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia




Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia

The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.

SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE) — Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Urocross^® Expander System (Urocross), a novel, non-permanent implant technology for treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

The Urocross procedures utilize commercially available flexible cystoscopes to place a non-permanent implant designed to remodel the obstructed prostatic tissue, which is then retrieved within six months. Where the Urocross procedure does not require permanent implant placement and avoids damage to prostatic tissue (no cutting, burning or ablating), future diagnostic and therapeutic treatment options are preserved.

The available long-term clinical data supporting FDA 510(k) Premarket clearance demonstrated sustained improvements in urinary symptoms, quality of life and urinary flow after Urocross retrieval with no negative impact on sexual function. The results support the system’s intended role in the management of LUTS associated with BPH.

Data Supporting the FDA 510(k) Clearance

The FDA 510(k) clearance of the Urocross^® Expander System was supported by a comprehensive body of data submitted to the Agency, including the Expander-1 Feasibility Trial and the Expander-2 Pivotal Trial, a large-scale multi-center 2:1 randomized controlled trial (RCT) of 240 patients from 23 sites across the US and Canada.

Key elements from Expander-2 Multi-center RCT submitted for the FDA clearance included:

• Mean improvement in International Prostate Symptom Score (IPSS) of 48.1% at 12 months post implantation (6 months post-retrieval)
• Procedural responder rate of 74.5%, defined by FDA as the percentage of patients with ≥ 30% IPSS improvement at 12-months
• No device or procedural-related serious adverse events in the Urocross treatment arm to date
• Preservation of sexual function, with no patients reporting de novo sustained erectile or ejaculatory dysfunction
• High level of procedure tolerability comparable to a diagnostic flexible cystoscopy

Urologists are increasingly recognizing the importance of earlier intervention in BPH to preserve bladder function and mitigate disease progression. “BPH is not solely a prostate condition; it is a bladder health issue,” said Dr. Kevin T. McVary, Professor of Urology at Loyola University Medical Center, and Co-Principal Investigator of the Expander-2 Trial. “Delaying intervention may contribute to irreversible bladder changes over time. New interventional technologies like Urocross enable minimally invasive approaches without permanent implants, providing safe and effective symptom relief with rapid recovery while preserving sexual function. These type of innovations might lower the threshold for patients to seek early intervention and represents a meaningful evolution in BPH care.”

“BPH management is not a singular intervention; it is a journey with longitudinal commitment to the patient’s evolving quality of life,” said Dr. Daniel B. Rukstalis, Chair of Urology at St. Catherine Hospital, Catholic Health System and Co-Principal Investigator of the Expander-2 Trial. “As minimally invasive options continue to expand, the clinical conversation is increasingly focused on how we balance clinical efficacy with long-term patient satisfaction. Technologies like Urocross that avoid permanent implants preserving future treatment options are becoming increasingly relevant in clinical decision-making of chronic diseases and well positioned as one of the first-line interventional therapy for BPH even before medications.”

“The FDA clearance of Urocross technology represents an important milestone for Prodeon and reflects our commitment to advancing therapies that balance durable symptom relief with patient and surgeon preferences,” said Thomas Palermo, President of Prodeon Medical. “Unlike existing minimally invasive therapies that rely on permanent implants or irreversible tissue ablation, Prodeon Medical introduces a new category of non-permanent, retrievable intervention for BPH, designed to remodel obstructive tissue while leaving no permanent foreign material behind. We plan to initiate a controlled US commercial release of the Urocross system later this year, and are excited to bring this transformative technology to market, offering a solution that is designed to prioritize clinical efficacy, patient quality of life, and minimize future risks.”

About Prodeon Medical

Prodeon Medical is a U.S.-based medical device company dedicated to developing innovative, minimally invasive solutions for urologic disease. The company is focused on advancing therapies designed to challenge conventional treatment paradigms while improving quality of life for patients.

About the Urocross^® Expander System

The Urocross^® Expander System is designed to remodel the obstructed prostatic urethra through a minimally invasive cystoscopy procedure using a non-permanent, intentionally retrievable implant. The implant remains in place for up to six months and is then retrieved, leaving no permanent foreign material behind, preserving future treatment options.

About Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting aging men in the United States. Approximately 40 million men in the U.S. are affected, with prevalence increasing significantly with age. Symptoms can worsen over time and negatively affect quality of life, sleep, and bladder health, contributing to growing demand for minimally invasive treatments that provide sustained relief while preserving future therapeutic options.

Media contact:
Tim Buckley, Executive Vice President
tim.buckley@prodeonmedical.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/61d213f2-f385-461d-ab50-eaf66a27e77a